Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months
Makaleler > Tam Makale · 2009
Yazarlar: Güray SAYDAM
International Journal of Hematology and Oncology, Uluslararası, Scopus, 2009, cilt 19, ss 195-204
DOI: 10.4999/uhod.2009.19.09137
Özet
This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94±4.53months.Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases.The last imatinib doses in chronic, accelerated and blastic phases were 609.72±171.29,714.29±106.90, and 569.23±160.13,respectively.Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively.Molecular response was evaluated by bcr/abl transcript levels in RT-PCR.Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases.Of 99 patients 77 (77.8%) were alive.16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis.No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events.Most patients had complete hematological response.Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects.